In 2000, KGI Biological Company was established.
200 1-KGI human gene database platform for drug target prediction and discovery was built and put into use.
In 2002, the design, preparation and verification of anti-tumor gene switch drugs were completed.
In 2003, the anti-tumor gene switch drug project completed the screening in vitro and in vivo.
In 2004, China, the United States, Japan and Europe applied for patents of gene switch drugs.
In 2005, the company transformed and developed biochemical reagent products, and cell lines and apoptosis detection products went on the market;
In 2006, protein research series products went on the market and began to attract investment to sell products;
In 2007, a series of molecular biology varieties went on the market, and related technical services were transformed at the same time;
In 2008, KGI products established a nationwide distribution network, and the company moved to a new address of 6,000 square meters.
In 2009, the company built a general tool library for life science, a medical research tool library, a drug discovery and development tool library, and a nuclear quality and nuclear signal research tool library, with more than 2,600 product specifications. Protein has also established four technical platforms: immunoassay, drug screening and evaluation, gene manipulation and cell biological detection, and its service capacity has doubled.
There are more than 5000 varieties of 20 10 biochemical reagents. Antibody platform construction, and gradually expand to the direction of diagnostic reagents.